← Design Therapeutics, Inc. (DSGN) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Design Therapeutics, Inc. (DSGN)
Pharmaceutical Preparations · market cap $781M · as of 2026-07-21
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
2
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Design Therapeutics (DSGN) is a small-cap (~$785M market cap, 55 employees) pharmaceutical company with two Phase 2 assets: DT-216P2 for Friedreich Ataxia and DT-168 for Fuchs Endothelial Corneal Dystrophy. The company has essentially no cash runway (~2.3 months, $12.8M cash) against an annual R&D burn exceeding $50M, making a near-term capital raise a near-certainty before key Phase 2 readouts expected in Q3 and Q4 2026.
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 2 · DT-216P2imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| DT-216P2 | Phase 2 | Friedreich Ataxia |
| DT-168 | Phase 2 | Fuchs Endothelial Corneal Dystrophy |
Price & technical context
3-month
-21.7%
6-month
+11.2%
12-month
+62.5%
52-wk range
$5.53–$15.94
vs 50-day MA
-11.2%
vs 200-day MA
+2.0%
Realized vol
74.6%
Max drawdown
-62.8%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for DSGN (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.